- Home
- HAIA vs AFMD Comparison
HAIA vs AFMD Comparison
Compare HAIA & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAIA
- AFMD
- Stock Information
- Founded
- HAIA 2021
- AFMD 2000
- Country
- HAIA United States
- AFMD Germany
- Employees
- HAIA N/A
- AFMD N/A
- Industry
- HAIA Blank Checks
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- HAIA Finance
- AFMD Health Care
- Exchange
- HAIA Nasdaq
- AFMD Nasdaq
- Market Cap
- HAIA 68.8M
- AFMD 55.6M
- IPO Year
- HAIA 2021
- AFMD 2014
- Fundamental
- Price
- HAIA $11.50
- AFMD $3.65
- Analyst Decision
- HAIA
- AFMD Strong Buy
- Analyst Count
- HAIA 0
- AFMD 5
- Target Price
- HAIA N/A
- AFMD $16.25
- AVG Volume (30 Days)
- HAIA 6.5K
- AFMD 98.0K
- Earning Date
- HAIA 01-01-0001
- AFMD 11-14-2024
- Dividend Yield
- HAIA N/A
- AFMD N/A
- EPS Growth
- HAIA N/A
- AFMD N/A
- EPS
- HAIA 0.13
- AFMD N/A
- Revenue
- HAIA N/A
- AFMD $7,959,927.00
- Revenue This Year
- HAIA N/A
- AFMD N/A
- Revenue Next Year
- HAIA N/A
- AFMD $48.98
- P/E Ratio
- HAIA $85.61
- AFMD N/A
- Revenue Growth
- HAIA N/A
- AFMD N/A
- 52 Week Low
- HAIA $10.84
- AFMD $2.92
- 52 Week High
- HAIA $11.53
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- HAIA 64.85
- AFMD 55.19
- Support Level
- HAIA $11.49
- AFMD $3.63
- Resistance Level
- HAIA $11.52
- AFMD $3.98
- Average True Range (ATR)
- HAIA 0.04
- AFMD 0.24
- MACD
- HAIA 0.00
- AFMD 0.04
- Stochastic Oscillator
- HAIA 83.81
- AFMD 55.65
About HAIA Healthcare AI Acquisition Corp.
Healthcare AI Acquisition Corp is a blank check company.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.